First human trial of SUPLEXA cells targets Hard-to-Treat cancers

NCT ID NCT05237206

Completed Disease control Sponsor: Alloplex Biotherapeutics Inc Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-stage trial tested a new therapy called SUPLEXA in 46 adults with advanced solid tumors or blood cancers that had spread. SUPLEXA is made from a patient's own immune cells, which are processed in a lab to become more active against cancer. The main goal was to check safety and find the right dose, with a secondary goal of seeing if tumors shrink. Because it is a Phase 1 study, it is too soon to know if this will become a standard treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SUPLEXA therapeutic cells (a mix of immune cells made from the patient's own blood)
What this could lead to: If it works, this could point toward a new way to treat advanced cancers that have not responded to other therapies.
What could go wrong: This is a very early, small Phase 1 trial focused on safety, not proof of effectiveness. The treatment may not shrink tumors or may cause side effects. Only solid tumor patients were enrolled, so results may not apply to blood cancers.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia lymphoma metastatic malignant neoplasm neoplasm plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ONCOLOGY

Contacts and locations

Locations

Cancer Research Sa (Crsa)

Adelaide, South Australia, 5000, Australia
Greenslopes Private Hospital/Gallipoli Medical Research Foundation

Brisbane, Queeensland, 4120, Australia
Southern Oncology Clinical Research Unit (SOCRU)

Adelaide, South Australia, 5042, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.